Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson
McKesson
Colorcon
McKinsey
Boehringer Ingelheim

Last Updated: June 27, 2022

CLINICAL TRIALS PROFILE FOR AVAPRITINIB


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Avapritinib

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02508532 ↗ (NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors Completed Blueprint Medicines Corporation Phase 1 2015-08-01 This is a Phase 1, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antineoplastic activity of avapritinib (formerly BLU-285), administered orally (PO), in adult patients with unresectable GIST or other relapsed or refractory solid tumors. The study consists of 2 parts, a dose-escalation part (Part 1) and an expansion part (Part 2).
NCT02561988 ↗ (EXPLORER) Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies Active, not recruiting Blueprint Medicines Corporation Phase 1 2016-03-10 This is a Phase 1, open-label, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antineoplastic activity of avapritinib (also known as BLU-285), administered orally (PO), in adult patients with advanced systemic mastocytosis and other relapsed or refractory myeloid malignancies. The study consists of 2 parts, a dose-escalation part (Part 1) and an expansion part (Part 2).
NCT03056599 ↗ Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma Completed Fred Hutchinson Cancer Research Center Phase 1 2016-12-15 This is a feasibility study in patients with localized or metastatic soft tissue sarcoma undergoing surgery to determine how sarcoma in situ responds to injected microdoses of anti-cancer therapeutics.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Avapritinib

Condition Name

Condition Name for Avapritinib
Intervention Trials
Gastrointestinal Stromal Tumors 3
Mast Cell Leukemia 2
Aggressive Systemic Mastocytosis 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Avapritinib
Intervention Trials
Gastrointestinal Stromal Tumors 6
Neoplasms 5
Mastocytosis 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Avapritinib

Trials by Country

Trials by Country for Avapritinib
Location Trials
United States 70
Canada 6
France 5
United Kingdom 5
Spain 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Avapritinib
Location Trials
New York 6
Texas 6
California 5
Massachusetts 5
Georgia 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Avapritinib

Clinical Trial Phase

Clinical Trial Phase for Avapritinib
Clinical Trial Phase Trials
Phase 4 1
Phase 3 1
Phase 2 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Avapritinib
Clinical Trial Phase Trials
Active, not recruiting 4
Completed 3
Not yet recruiting 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Avapritinib

Sponsor Name

Sponsor Name for Avapritinib
Sponsor Trials
Blueprint Medicines Corporation 9
Fred Hutchinson Cancer Research Center 1
Northwell Health 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Avapritinib
Sponsor Trials
Industry 12
Other 5
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Boehringer Ingelheim
Baxter
McKinsey
Moodys
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.